Boston Scientific’s Q2 2026 results highlight broad-based organic revenue growth across most business segments, driven by innovations in cardiovascular and neuromodulation devices. The company faces headwinds in its Urology segment due to volume procurement pressures in China. Strategic portfolio management, including discontinuation of lower-potential products and investments in R&D, underpin its efforts to strengthen competitive positioning globally. Emerging markets remain a key growth avenue, albeit with execution risks. Boston Scientific maintains strong liquidity and covenant compliance amid active debt management and restructuring initiatives.